Actively Recruiting
Evaluating Oral Nizubaglustat AZ-3102 for Late-infantile and Juvenile Niemann-Pick Type C Disease An 18-month Randomized, Placebo-Controlled Trial
Led by Azafaros B.V. · Updated on 2026-10-28
72
Participants Needed
34
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an 18-month Phase 3 clinical trial to study the safety and efficacy of oral nizubaglustat AZ-3102 in children and young people aged 4 years and older with late-infantile and juvenile forms of Niemann-Pick Type C NPC disease. This randomized, double-blind, placebo-controlled study aims to compare the effects of nizubaglustat against placebo on ataxic symptoms and other disease manifestations in this rare neurological condition. Participants will receive once-daily oral dispersible tablets of either nizubaglustat or a matching placebo over 18 months. The study examines the drugs pharmacokinetics and pharmacodynamics, along with its safety and tolerability. The trial is conducted at multiple centers and includes a parallel study design where participants are randomly assigned to one of the two groups. Throughout the study, participants will undergo regular assessments including the Scale for the Assessment and Rating of Ataxia SARA, Vineland Adaptive Behavior Scale, Penetration-Aspiration Scale, and several other evaluations at baseline and at months 6, 12, and 18. Researchers will also monitor seizure frequency and drug plasma levels, as well as record any adverse effects. The primary outcomes focus on changes in ataxia scores over the 18-month period to evaluate the treatments impact.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Research Team
P
Patient Advocacy Representative
C
Contact for Healthcare Professionals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here